Baseline (year 1) phenotype characteristics prior to COPD diagnosis
Variables | Phenotype | ||
A (n=4339) | B (n=1040) | C (n=6103) | |
Age, mean (SD), years | 69 (9) | 73 (8) | 68 (10) |
Sex, male, no. (%) | 2456 (57) | 799 (77) | 3271 (54) |
Body mass index, mean (SD), kg/m2 | 27 (6) | 29 (5) | 27 (5) |
Body mass index, no. (%) with data | 4311 (99) | 1040 (100) | 6058 (99) |
Underweight | 1618 (38) | 220 (21) | 2228 (37) |
Normal weight | 1029 (24) | 381 (37) | 1460 (24) |
Overweight | 1479 (34) | 427 (41) | 2164 (36) |
Obese | 185 (4) | 12 (1) | 206 (3) |
Smoking status, no. (%) | |||
Active smoker | 1542 (36) | 306 (29) | 2619 (43) |
Former smoker | 2797 (64) | 734 (71) | 3484 (57) |
COPD severity, no. (%) with data | 2481 (57) | 556 (54) | 2822 (46) |
Mild | 587 (24) | 174 (31) | 1196 (42) |
Moderate | 1154 (46) | 316 (57) | 1361 (48) |
Severe | 666 (27) | 62 (11) | 247 (9) |
Very severe | 74 (3) | 4 (1) | 18 (1) |
COPD exacerbations in the past year, mean (SD) | 0.5 (1.2) | 0.2 (0.7) | 0.1 (0.8) |
COPD exacerbations in the past year, no. (%) | |||
0 | 3323 (77) | 899 (86) | 5514 (90) |
1 | 497 (11) | 85 (8) | 416 (7) |
2 | 266 (6) | 36 (4) | 131 (2) |
>2 | 253 (6) | 20 (2) | 42 (1) |
Forced expiratory volume in 1 s, mean (SD), L | 0.7 (0.2) | 0.7 (0.2) | 0.8 (0.2) |
Emphysema, no. (%) | 308 (7) | 59 (6) | 279 (5) |
Diabetes, no. (%) | 597 (14) | 382 (37) | 792 (13) |
Hypertension, no. (%) | 1948 (45) | 703 (68) | 2666 (44) |
Coronary artery disease, no. (%) | 33 (1) | 617 (59) | 25 (0.4) |
Acute myocardial infarction, no. (%) | 75 (2) | 681 (66) | 66 (1) |
Congestive cardiac failure, no. (%) | 223 (5) | 304 (29) | 192 (3) |
Anxiety, no. (%) | 319 (7) | 101 (10) | 518 (9) |
Depression, no. (%) | 1279 (30) | 348 (34) | 1863 (31) |
Treatment, no. (%) | |||
ICS | 4290 (99) | 408 (39) | 384 (6) |
ICS+LABA | 4141 (95) | 339 (33) | 6 (0.1) |
LAMA | 3022 (70) | 437 (42) | 1904 (31) |
LABA | 227 (5) | 92 (9) | 780 (12.8) |
SAMA | 206 (5) | 64(6) | 311 (5) |
Mucolytics | 756 (17) | 108 (10) | 164 (23) |
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LAMA, long-acting antimuscarinic; SAMA, short-acting antimuscarinic.